The dual CCR5/CCR2 inhibitor cenicriviroc demonstrated good antiviral activity and tolerability in a Phase 2 clinical trial, according to a report at the 14th European AIDS Conference this week in Brussels.
http://www.hivandhepatitis.com/hiv-treatment/experimental-hiv-drugs/4361-eacs-2013-cenicriviroc-shows-good-activity-against-hiv-new-formulation-may-reduce-dropouts
http://www.hivandhepatitis.com/hiv-treatment/experimental-hiv-drugs/4361-eacs-2013-cenicriviroc-shows-good-activity-against-hiv-new-formulation-may-reduce-dropouts
No comments:
Post a Comment